Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
| Autor: | A. E. Nikitin, E. E. Averin, D. E. Rozhkov, G. A. Procenko, Alexey Sozykin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Urology Low density lipoprotein cholesterol alirocumab RM1-950 Disease 030204 cardiovascular system & hematology low density lipoprotein cholesterol Persistence (computer science) 03 medical and health sciences 0302 clinical medicine cardiovascular disease Diseases of the circulatory (Cardiovascular) system Medicine Pharmacology (medical) Alirocumab Secondary prevention target level business.industry PCSK9 Lipid metabolism RC666-701 pcsk9 inhibitors Kexin lipids (amino acids peptides and proteins) Therapeutics. Pharmacology atherosclerosis Cardiology and Cardiovascular Medicine business secondary prevention 030217 neurology & neurosurgery |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 1, Pp 33-39 (2020) |
| ISSN: | 2225-3653 1819-6446 |
| DOI: | 10.20996/1819-6446-2020-02-06 |
| Popis: | Aim. To study the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid levels in patients who receive secondary prevention of cardiovascular diseases (CVD) and require enhanced lipid-lowering therapy.Material and methods. The study included 49 patients (aged of 61.53±1.14 years; 31 [63.3%] men) receiving alirocumab who did not reach the target low density lipoprotein cholesterol (LDL-C) concentrations despite the ongoing optimal lipid-lowering therapy. In all patients, the initial level of lipids was evaluated, as well as their parameters after subsequent alirocumab injections.Results. LDL-C serum level significantly decreased after the first injection compared to the initial level from 2.92±0.22 to 1.65±0.19 mmol/L (pConclusion. The results of the study indicate that the PCSK9 inhibitor, alirocumab, in patients who need secondary prevention of CVD shows a significant additional decrease in the concentration of LDL-C after the first injection. At the same time, approximately half of the patients were able to achieve the recommended levels of LDL-C. The persistence of the achieved low LDL-C levels over time demonstrated that the average concentration of LDL-C during the observation corresponded to the values after the first injection. This finding shows that there is no need for constant monitoring of lipid metabolism parameters when prescribing such therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|